Founded in 2016, TrueBinding Inc. is a clinical stage biotherapeutic company creating new and exciting molecules for applications in neurodegenerative diseases (AD, PD, ALS), stroke, metabolic diseases, oncology and other disease areas with great unmet medical need.

TrueBinding selected Mediso over other purveyors of this technology, as Mediso provides the highest levels of technical excellence in both PET and MRI and has the longest track record of quantitatively fusing the combined PET and MRI images. Mediso and TrueBinding fully expect significant therapeutic advances evolving from this collaborative scientific relationship.